SCHEMBL4474440

SCHEMBL4474440

CCCCCNCCCN

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.72
CA12 O43570 2/20 0.72
F13A1 P00488 2/20 0.72
CA2 P00918 2/20 0.72
CYP1A2 P05177 2/20 0.72
ALOX15 P16050 2/20 0.72
CA4 P22748 2/20 0.72
CA6 P23280 2/20 0.72
CA5A P35218 2/20 0.72
THPO P40225 2/20 0.72
CA7 P43166 2/20 0.72
CA9 Q16790 2/20 0.72
CA14 Q9ULX7 2/20 0.72
CA5B Q9Y2D0 2/20 0.72
CASP2 P42575 2/20 0.72
ALDH1A1 P00352 2/20 0.72
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
CYP2C19 P33261 1/20 0.72
RECQL P46063 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13522294 1.00 TSHR (0.72) TSHRCA12F13A1CA2CYP1A2
SCHEMBL197215 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL11881064 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL443775 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL2166878 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL964709 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL962833 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL9807857 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
SCHEMBL22580330 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2
Methane SCHEMBL4539643 0.97 TSHR (0.68) TSHRCA12F13A1CA2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022167700-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER Floratek Pharma SA (CH) 2022-08-11 WO claimed
EP-2098316-A2 Metal nanoparticles stabilized with a bident amine Xerox Corporation (US) 2009-09-09 EP claimed
US-20090214764-A1 METAL NANOPARTICLES STABILIZED WITH A BIDENT AMINE XEROX CORPORATION (US) 2009-08-27 US claimed
US-4292411-A ORGANIC BISMUTH COMPOUND, PRIMARY OR SECONDARY AMINE S.A. PRB (BE) 1981-09-29 US claimed
US-4150206-A SYNERGISTIC CATALYSTS S.A. PRB (BE) 1979-04-17 US claimed
US-3937856-A REHABILITATION OF WATER-DAMAGED ELECTRICAL EQUIPMENT UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-02-10 US claimed
EP-3623398-B1 RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER ASAHI CHEMICAL IND (JP) 2024-08-28 EP disclosed
US-20240132461-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER FLORATEK PHARMA S A (CH) 2024-04-25 US disclosed
EP-4288421-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER Floratek Pharma SA (CH) 2023-12-13 EP disclosed
EP-4288421-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER Floratek Pharma SA (CH) 2023-12-13 EP disclosed
WO-2023208988-A1 ANTIBACTERIAL COMPOUNDS ELIMINATING DORMANT BACTERIAL CELLS UNIVERSITÉ D'AIX-MARSEILLE (FR) 2023-11-02 WO disclosed
US-20230313195-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE Suzhou Ribo Life Science Co., Ltd. (CN) 2023-10-05 US disclosed
US-20230302138-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS RECODE THERAPEUTICS, INC. 2023-09-28 US disclosed
EP-2098316-A2 Metal nanoparticles stabilized with a bident amine Xerox Corporation (US) 2009-09-09 EP disclosed
US-20090214764-A1 METAL NANOPARTICLES STABILIZED WITH A BIDENT AMINE XEROX CORPORATION (US) 2009-08-27 US disclosed
US-7517913-B2 Polyamine conjugates with acidic retinoids and preparation thereof PAPAIOANNOU DIONYSIOS 2009-04-14 US disclosed
US-20080299669-A1 Methods and devices for analytical sensing of biogenic amines SOUTH CAROLINA, UNIVERSITY OF 2008-12-04 US disclosed
US-7208528-B1 Polyamine analogues as therapeutic and diagnostic agents MEDIQUEST THERAPEUTICS, INC. (US) 2007-04-24 US disclosed
US-4003718-A Substituted tetrahydropyrimidines UNIVERSAL OIL PRODUCTS COMPANY (US) 1977-01-18 US disclosed
US-3937856-A REHABILITATION OF WATER-DAMAGED ELECTRICAL EQUIPMENT UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230302138-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS CHMP4B, LIPA, NPC1L1 TSHR 2262/4885CA12 986/4885F13A1 1134/4885
US-20240132461-A1 FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER SRM, TP53, KDM5A TSHR 4358/4885CA12 2797/4885F13A1 2114/4885
US-20230313195-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE PCSK9, PCSK7, PCSK6 TSHR 4123/4885CA12 4469/4885F13A1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.